Information Provided By: 
Fly News Breaks for March 13, 2018
SRPT
Mar 13, 2018 | 07:22 EDT
Leerink analyst Joseph Schwartz raised his price target for Sarepta Therapeutics to $92 saying the earlier than expected new drug application filing for golodirsen renders a 2019 market entry likely. The analyst also sees yesterday's announcement as a positive read-through to casimersen, which he believes may undergo a similar trajectory pending further discussions with the FDA. Schwartz increased his probabilities of success for golodirsen/casimersen to 75%/45% from 45%/30% and reiterates an Outperform rating on Sarepta shares.
News For SRPT From the Last 2 Days
There are no results for your query SRPT
